HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Analysis of Target Molecules towards Anti-cancer Therapeutic Antibodies].

Abstract
Target molecules of existing anti-cancer therapeutic monoclonal antibodies (mAbs) are divided into 1) receptor-type tyrosine kinases, such as human epidermal growth factor receptor (HER) family, 2) differentiation antigens, such as CD20 (Rituxan target), 3) angiogenesis-related molecules, and 4) immune checkpoint molecules (PD-1, etc.). We have recently reported a novel therapy targeting lymphangiogenesis, but not angiogenesis, using an anti-LYVE-1 (lymphatic vessel endothelial hyaluronan receptor 1) mAb. At present, many transporters are not considered to be target molecules for the cancer therapy; however, our study strongly suggested that the inhibition of cancer metabolism by mAbs against amino acid transporters will play a significant role in future cancer therapies. Most anti-cancer therapeutic mAbs bind cell-surface molecules on viable cancer cells: therefore, it is necessary to produce mAbs recognizing epitopes on the extracellular domains of native and non-denatured proteins. We concluded that viable cancer cells or cells transfected with cDNA encoding target proteins are suitable immunogens for the production of anti-cancer therapeutic mAbs. We introduce our efforts to develop seeds for therapeutic mAbs using whole cancer cells and transfectants as the immunogen. As many target candidates in the future are multi-pass membrane proteins, such as 12-pass amino acid transporter proteins belonging to the solute carrier (SLC) family, and their possible immunogenic extracellular regions are small, the production of specific mAbs is highly difficult. In this review, we summarize the successful preparation and characterization of mAbs recognizing the extracellular domain of oncoproteins, including transporters.
AuthorsTakashi Masuko
JournalYakugaku zasshi : Journal of the Pharmaceutical Society of Japan (Yakugaku Zasshi) Vol. 141 Issue 1 Pg. 81-92 ( 2021) ISSN: 1347-5231 [Electronic] Japan
PMID33390451 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, CD20
  • LYVE1 protein, human
  • Membrane Transport Proteins
  • Oncogene Proteins
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Vesicular Transport Proteins
  • Rituximab
  • ERBB2 protein, human
  • Receptor, ErbB-2
Topics
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Antigens, CD20
  • Humans
  • Membrane Transport Proteins
  • Mice
  • Molecular Targeted Therapy
  • Neoplasms (drug therapy, genetics)
  • Oncogene Proteins
  • Programmed Cell Death 1 Receptor
  • Rats
  • Receptor, ErbB-2
  • Rituximab
  • Vesicular Transport Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: